The Clatterbridge Cancer Centre, Wirral, UK
Search for other papers by Anna Olsson-Brown in
Google Scholar
PubMed
Search for other papers by Rosemary Lord in
Google Scholar
PubMed
Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, UK
Search for other papers by Joseph Sacco in
Google Scholar
PubMed
Search for other papers by Jonathan Wagg in
Google Scholar
PubMed
Search for other papers by Mark Coles in
Google Scholar
PubMed
Search for other papers by Munir Pirmohamed in
Google Scholar
PubMed
monotherapy ICI was 12 weeks (range 6–18 weeks; IQR 6 weeks). The trough T4 prior to commencement of levothyroxine was 4.45 pmol/L (95% CI 0.4–8.5 pmol/L), with an associated peak TSH of 69.0 mU/L (95% CI 44.7–93.2 mU/L). Figure 2 Changes of TSH (black
Search for other papers by Xiaoya Zheng in
Google Scholar
PubMed
Search for other papers by Shanshan Yu in
Google Scholar
PubMed
Search for other papers by Jian Long in
Google Scholar
PubMed
Search for other papers by Qiang Wei in
Google Scholar
PubMed
Search for other papers by Liping Liu in
Google Scholar
PubMed
Search for other papers by Chun Liu in
Google Scholar
PubMed
Search for other papers by Wei Ren in
Google Scholar
PubMed
having an elevated TSH value >5.91 µIU/mL or being on levothyroxine replacement therapy at the time of diagnosis. The diagnosis of HT was suggested by a typical ultrasound pattern or by the presence of antithyroid antibodies ( 17 ). Statistical
Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel
Search for other papers by Amir Bashkin in
Google Scholar
PubMed
Search for other papers by Eliran Yaakobi in
Google Scholar
PubMed
Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel
Search for other papers by Marina Nodelman in
Google Scholar
PubMed
Department of Otolaryngology Head and Neck Surgery, Galilee Medical Center, Nahariya, Israel
Search for other papers by Ohad Ronen in
Google Scholar
PubMed
glucocorticoids, levothyroxine, Mercaptizol, Propylthiouracil, Amiodarone, opioids and drugs that enhance T4 metabolism through the enhancement of cytochrome P450 3A4 such as phenytoin and carbamazepine ( 5 , 6 ). Patients were divided into the following
Search for other papers by Adriano N Cury in
Google Scholar
PubMed
Search for other papers by Verônica T Meira in
Google Scholar
PubMed
Pediatric Endocrinology Unit, Endocrinology and Metabolism, Nuclear Medicine Laboratory, Pediatrics Department, Irmandade da Santa Casa de Misericórdia de São Paulo, 01221-020 São Paulo, Brazil
Search for other papers by Osmar Monte in
Google Scholar
PubMed
Search for other papers by Marília Marone in
Google Scholar
PubMed
Search for other papers by Nilza M Scalissi in
Google Scholar
PubMed
Search for other papers by Cristiane Kochi in
Google Scholar
PubMed
Search for other papers by Luís E P Calliari in
Google Scholar
PubMed
Search for other papers by Carlos A Longui in
Google Scholar
PubMed
medications. Treatment period of ATD therapy was 16.9 (11.4) months. Levothyroxine ( l -T 4 ) was used in all patients who progressed to hypothyroidism after RAI therapy. No patient was subjected to ‘block and replace’ treatment. The chief criteria that were
Search for other papers by Paolo G Arduino in
Google Scholar
PubMed
Search for other papers by Dora Karimi in
Google Scholar
PubMed
Search for other papers by Federico Tirone in
Google Scholar
PubMed
Search for other papers by Veronica Sciannameo in
Google Scholar
PubMed
Search for other papers by Fulvio Ricceri in
Google Scholar
PubMed
Search for other papers by Marco Cabras in
Google Scholar
PubMed
Search for other papers by Alessio Gambino in
Google Scholar
PubMed
Search for other papers by Davide Conrotto in
Google Scholar
PubMed
Search for other papers by Stefano Salzano in
Google Scholar
PubMed
Search for other papers by Mario Carbone in
Google Scholar
PubMed
Search for other papers by Roberto Broccoletti in
Google Scholar
PubMed
consider normal function of the thyroid gland, were between 9.0 and 25.0 pmol/L for fT 4 , and between 0.4 and 4.0 milliunits per litre (U/L) for TSH. Patients with the abnormal test were referred to an endocrinologist. Levothyroxine was the most commonly
Department of Endocrinology, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK
Search for other papers by Sophie Howarth in
Google Scholar
PubMed
Search for other papers by Luca Giovanelli in
Google Scholar
PubMed
Search for other papers by Catherine Napier in
Google Scholar
PubMed
Department of Endocrinology, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK
Search for other papers by Simon H Pearce in
Google Scholar
PubMed
history included levothyroxine 200 µg once daily, 3-monthly vitamin B12 injections, an actrapid/glargine basal bolus insulin regimen and the combined oral contraceptive pill (COCP). Eight years previously, she had been hospitalised for an episode of
Search for other papers by Selma Flora Nordqvist in
Google Scholar
PubMed
Search for other papers by Victor Brun Boesen in
Google Scholar
PubMed
Search for other papers by Åse Krogh Rasmussen in
Google Scholar
PubMed
Institute of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark
Search for other papers by Ulla Feldt-Rasmussen in
Google Scholar
PubMed
Search for other papers by Laszlo Hegedüs in
Google Scholar
PubMed
Search for other papers by Steen Joop Bonnema in
Google Scholar
PubMed
Search for other papers by Per Karkov Cramon in
Google Scholar
PubMed
Department of Internal Medicine, Herlev Gentofte Hospital, Copenhagen, Denmark
Search for other papers by Torquil Watt in
Google Scholar
PubMed
Department of Palliative Medicine, Bispebjerg Hospital, Copenhagen, Denmark
Search for other papers by Mogens Groenvold in
Google Scholar
PubMed
National Research Centre for the Working Environment, Copenhagen, Denmark
QualityMetric Incorporated, LLC, Johnston, Rhode Island, USA
Search for other papers by Jakob Bue Bjorner in
Google Scholar
PubMed
) Autoimmune hypothyroidism 86 (20) Other thyroid diagnoses 18 (4) Disease duration (months) 0.3 (0–4) Treatment instituted Levothyroxine 111 (26) Antithyroid medication 86 (20) Aspiration of thyroid cyst 4
Department of Oncology, Comprehensive Cancer Centre, Helsinki University Hospital, Helsinki, Finland
Search for other papers by Hanna Karhapää in
Google Scholar
PubMed
Department of Oncology, Comprehensive Cancer Centre, Helsinki University Hospital, Helsinki, Finland
Search for other papers by Siru Mäkelä in
Google Scholar
PubMed
Department of Radiology, HUS Medical Imaging Centre, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
Search for other papers by Hanna Laurén in
Google Scholar
PubMed
Department of Radiology, HUS Medical Imaging Centre, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
Search for other papers by Marjut Jaakkola in
Google Scholar
PubMed
Endocrinology, Abdominal Centre, University of Helsinki and HUS, Helsinki, Finland
Search for other papers by Camilla Schalin-Jäntti in
Google Scholar
PubMed
Department of Oncology, Comprehensive Cancer Centre, Helsinki University Hospital, Helsinki, Finland
Search for other papers by Micaela Hernberg in
Google Scholar
PubMed
patients (12%) had a borderline level of TSHRAbs, and 7 patients (5%) had elevated TPOAbs. Prior to ICI treatment, 19 patients (14%) had primary hypothyroidism and were on levothyroxine treatment. None of the patients with a previous diagnosis of
Search for other papers by Lian Duan in
Google Scholar
PubMed
Search for other papers by Han-Yu Zhang in
Google Scholar
PubMed
Search for other papers by Min Lv in
Google Scholar
PubMed
Search for other papers by Han Zhang in
Google Scholar
PubMed
Search for other papers by Yao Chen in
Google Scholar
PubMed
Search for other papers by Ting Wang in
Google Scholar
PubMed
Search for other papers by Yan Li in
Google Scholar
PubMed
Search for other papers by Yan Wu in
Google Scholar
PubMed
Search for other papers by Junfeng Li in
Google Scholar
PubMed
Search for other papers by Kefeng Li in
Google Scholar
PubMed
and complex interactions among multiple predictive variables ( 15 ). However, to date, the application of machine learning approaches in thyroid-related diseases has primarily focused on the ultrasonic diagnosis or the optimization of levothyroxine
Search for other papers by W J Bom in
Google Scholar
PubMed
Search for other papers by F B M Joosten in
Google Scholar
PubMed
Search for other papers by M M G J van Borren in
Google Scholar
PubMed
Search for other papers by E P Bom in
Google Scholar
PubMed
Search for other papers by R R J P van Eekeren in
Google Scholar
PubMed
Search for other papers by H de Boer in
Google Scholar
PubMed
, and was treated with levothyroxine (50–125 µg daily). Two other patients were also on levothyroxine treatment, one because of Hashimoto’s disease and one because of hypothyroidism of unknown cause. The median nodule volume at baseline was 12.0 mL